IBPI completes Protegrin Phase III enrollment

IntraBiotics (IBPI) completed enrollment in a Phase III study of its Protegrin IB-367 synthetic

Read the full 148 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE